FDA approves AI-powered DermaSensor for enhanced skin cancer evaluation

The U.S. Food and Drug Administration (FDA) has recently authorized the marketing of the DermaSensor Inc. DermaSensor device, a potential advancement in the detection and evaluation of skin cancer. This AI-powered hand-held device is designed to assist healthcare providers in evaluating skin lesions suggestive of melanoma, basal cell carcinoma, and squamous cell carcinoma in patients aged 40 and over. The DermaSensor device is a prescription tool intended to aid non-dermatologist physicians in determining whether a patient should be referred to a dermatologist. It uses a combination of AI and light-based technology to analyze skin lesi......

Read Full article on HadNews

Comments

Popular posts from this blog

Beach day with my sisters in Gran Canaria - Video

Snowy Day Baking in the Village: Making Fruit Bread